Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

(2018) Toby M Maher et al.   Lancet Respiratory Medicine

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis

(2017) Nicolas Desroy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters

(2017) Anna Michalczyk et al.   Lipids in Health and Disease

Autotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation

(2013) Gye Young Park et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass

(2011) Isabelle Gennero et al.   BONE

LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis

(2010) H. Sumida et al.   BLOOD

High-Throughput Analysis of Sphingosine 1-Phosphate, Sphinganine 1-Phosphate, and Lysophosphatidic Acid in Plasma Samples by Liquid Chromatography-Tandem Mass Spectrometry

(2009) M. Scherer et al.   CLINICAL CHEMISTRY

Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus

(2008) Elisa Matas-Rico et al.   MOLECULAR AND CELLULAR NEUROSCIENCE